Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Future Oncol. 2024;20(22):1545-1552. doi: 10.1080/14796694.2024.2355080. Epub 2024 Jun 12.
Aim of this explorative pilot study was to evaluate the capability of an electronic nose (aeoNose, the eNose Company) to classify healthy individuals and patients with chondrosarcoma, based on their volatile organic compound profiles in exhaled breath. Fifty-seven patients (25 healthy controls, 24 chondrosarcoma and 8 different benign lesions) were included in the study from 2018 to 2023. An artificial neural network was used as classifier. The developed model had a sensitivity of 75%, and a specificity of 65% with an AUC of 0.66. Results show that there is not enough evidence to include the aeoNose as diagnostic biomarker for chondrosarcoma in daily practice. However, the aeoNose might play an additional role alongside MRI, in questionable chondrosarcoma cases.
本探索性初步研究旨在评估电子鼻 (aeoNose，eNose 公司) 基于呼气中挥发性有机化合物图谱，对健康个体和软骨肉瘤患者进行分类的能力。2018 年至 2023 年期间，共纳入 57 名患者（25 名健康对照、24 名软骨肉瘤和 8 名不同良性病变）。采用人工神经网络作为分类器。所开发的模型具有 75%的灵敏度和 65%的特异性，AUC 为 0.66。结果表明，没有足够的证据将 aeoNose 作为软骨肉瘤的诊断生物标志物纳入日常实践。然而，在有疑问的软骨肉瘤病例中，电子鼻可能与 MRI 一起发挥额外的作用。
